150 related articles for article (PubMed ID: 35946590)
21. Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative.
Huang GD; Bull J; Johnston McKee K; Mahon E; Harper B; Roberts JN;
Contemp Clin Trials; 2018 Mar; 66():74-79. PubMed ID: 29330082
[TBL] [Abstract][Full Text] [Related]
22. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years.
Walter S; Langford OG; Clanton TB; Jimenez-Maggiora GA; Raman R; Rafii MS; Shaffer EJ; Sperling RA; Cummings JL; Aisen PS
J Prev Alzheimers Dis; 2020; 7(4):234-241. PubMed ID: 32920625
[TBL] [Abstract][Full Text] [Related]
23. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials.
Grill JD; Karlawish J
Alzheimers Res Ther; 2010 Dec; 2(6):34. PubMed ID: 21172069
[TBL] [Abstract][Full Text] [Related]
24. Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions.
Carlsson CM
J Alzheimers Dis; 2008 Oct; 15(2):327-38. PubMed ID: 18953117
[TBL] [Abstract][Full Text] [Related]
25. Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
Grill JD; Zhou Y; Elashoff D; Karlawish J
Neurobiol Aging; 2016 Mar; 39():147-53. PubMed ID: 26923411
[TBL] [Abstract][Full Text] [Related]
26. Design of comprehensive Alzheimer's disease centers to address unmet national needs.
Trojanowski JQ; Arnold SE; Karlawish JH; Brunden K; Cary M; Davatzikos C; Detre J; Gaulton G; Grossman M; Hurtig H; Jedrziewski K; McCluskey L; Naylor M; Polsky D; Schellenberg GD; Siderowf A; Shaw LM; Van Deerlin V; Wang LS; Werner R; Xie SX; Lee VM
Alzheimers Dement; 2010 Mar; 6(2):150-5. PubMed ID: 20298979
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers for Alzheimer's disease therapeutic trials.
Hampel H; Wilcock G; Andrieu S; Aisen P; Blennow K; Broich K; Carrillo M; Fox NC; Frisoni GB; Isaac M; Lovestone S; Nordberg A; Prvulovic D; Sampaio C; Scheltens P; Weiner M; Winblad B; Coley N; Vellas B;
Prog Neurobiol; 2011 Dec; 95(4):579-93. PubMed ID: 21130138
[TBL] [Abstract][Full Text] [Related]
28. The Patient in Your Alzheimer's Disease Study May be in Another: Duplication and Deception in Clinical Trials of Alzheimer's Disease.
Shiovitz T; Steinmiller B; Steinmetz C; Perez S; Oseas R
J Prev Alzheimers Dis; 2020; 7(1):43-46. PubMed ID: 32010925
[TBL] [Abstract][Full Text] [Related]
29. Prevention trials in Alzheimer's disease: an EU-US task force report.
Vellas B; Aisen PS; Sampaio C; Carrillo M; Scheltens P; Scherrer B; Frisoni GB; Weiner M; Schneider L; Gauthier S; Gispen-de Wied CC; Hendrix S; Feldman H; Cedarbaum J; Petersen R; Siemers E; Andrieu S; Prvulovic D; Touchon J; Hampel H
Prog Neurobiol; 2011 Dec; 95(4):594-600. PubMed ID: 21925234
[TBL] [Abstract][Full Text] [Related]
30. A collaborative Alzheimer disease research exchange using a community-based Helpline as a recruitment tool.
Austrom MG; Bachman J; Altmeyer L; Gao S; Farlow M
Alzheimer Dis Assoc Disord; 2010; 24 Suppl():S49-53. PubMed ID: 22720321
[TBL] [Abstract][Full Text] [Related]
31. Improving recruitment, retention, and adherence to 6-month cycling in Alzheimer's disease.
Yu F
Geriatr Nurs; 2013; 34(3):181-6. PubMed ID: 23414638
[TBL] [Abstract][Full Text] [Related]
32. Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective.
Hampel H; Prvulovic D
J Nutr Health Aging; 2012 Apr; 16(4):346-8. PubMed ID: 22499455
[TBL] [Abstract][Full Text] [Related]
33. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
34. Carer impressions of participation in Alzheimer's disease clinical trials: what are their hopes? And is it worth it?
Mastwyk M; Ritchie CW; LoGiudice D; Sullivan KA; Macfarlane S
Int Psychogeriatr; 2002 Mar; 14(1):39-45. PubMed ID: 12094906
[TBL] [Abstract][Full Text] [Related]
35. Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment.
Schneider LS
Alzheimer Dis Assoc Disord; 2005; 19(4):279-83. PubMed ID: 16327360
[TBL] [Abstract][Full Text] [Related]
36. Motivators for Alzheimer's disease clinical trial participation.
Bardach SH; Holmes SD; Jicha GA
Aging Clin Exp Res; 2018 Feb; 30(2):209-212. PubMed ID: 28523610
[TBL] [Abstract][Full Text] [Related]
37. Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.
Faison WE; Schultz SK; Aerssens J; Alvidrez J; Anand R; Farrer LA; Jarvik L; Manly J; McRae T; Murphy GM; Olin JT; Regier D; Sano M; Mintzer JE
Int Psychogeriatr; 2007 Jun; 19(3):539-58. PubMed ID: 17451614
[TBL] [Abstract][Full Text] [Related]
38. Recruitment across two decades of NIH-funded Alzheimer's disease clinical trials.
Ritchie M; Gillen DL; Grill JD
Alzheimers Res Ther; 2023 Feb; 15(1):28. PubMed ID: 36732846
[TBL] [Abstract][Full Text] [Related]
39. Learning from recruitment challenges: barriers to diagnosis, treatment, and research participation for Latinos with symptoms of Alzheimer's disease.
Gelman CR
J Gerontol Soc Work; 2010 Jan; 53(1):94-113. PubMed ID: 20029704
[TBL] [Abstract][Full Text] [Related]
40. Challenges, solutions, and recommendations for Alzheimer's disease combination therapy.
Hendrix JA; Bateman RJ; Brashear HR; Duggan C; Carrillo MC; Bain LJ; DeMattos R; Katz RG; Ostrowitzki S; Siemers E; Sperling R; Vitolo OV
Alzheimers Dement; 2016 May; 12(5):623-30. PubMed ID: 27017906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
